Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All tixagevimab/cilgavimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Management of immunosuppression in lung transplant recipients and COVID-19 outcomes: an observational retrospective cohort-study

Bes-Berlandier et al., BMC Infectious Diseases, doi:10.1186/s12879-024-09269-1
May 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Oxygen increase, ICU, o.. -10% Improvement Relative Risk Tixagevimab/c..  Bes-Berlandier et al.  Prophylaxis Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 91 patients in France (March 2020 - April 2022) Study underpowered to detect differences c19early.org Bes-Berlandier et al., BMC Infectious .., May 2024 Favorstixagevimab/ci.. Favorscontrol 0 0.5 1 1.5 2+
38th treatment shown to reduce risk in May 2022
 
*, now with p = 0.000029 from 17 studies, recognized in 31 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 98 treatments. c19early.org
Retrospective 91 lung transplant recipients with COVID-19 showing no significant difference in poor outcomes with casirivimab/imdevimab or tixagevimab/cilgavimab prophylaxis in univariate analysis.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.13.
Study covers casirivimab/imdevimab and tixagevimab/cilgavimab.
oxygen increase, ICU, or mortality, 10.0% higher, RR 1.10, p = 1.00, treatment 3 of 14 (21.4%), control 15 of 77 (19.5%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bes-Berlandier et al., 28 May 2024, retrospective, France, peer-reviewed, median age 51.0, 10 authors, study period March 2020 - April 2022. Contact: cassirnadim@gmail.com.
This PaperTixagev../c..All
Management of immunosuppression in lung transplant recipients and COVID-19 outcomes: an observational retrospective cohort-study
Hugo Bes-Berlandier, Benjamin Coiffard, Julien Bermudez, Nadine Demazes-Dufeu, Bérengère Coltey, Céline Boschi, Philippe Colson, Sami Hraiech, Martine Reynaud-Gaubert, Nadim Cassir
BMC Infectious Diseases, doi:10.1186/s12879-024-09269-1
Background The aim of this study was to assess the impact of immunosuppression management on coronavirus disease 2019 (COVID-19) outcomes. Methods We performed a single-center retrospective study in a cohort of 358 lung transplant recipients (LTx) over the period from March 2020 to April 2022. All included symptomatic patients had at least one positive SARS-CoV-2 rt-PCR. We used a composite primary outcome for COVID-19 including increased need for oxygen since the hospital admission, ICU transfer, and in-hospital mortality. We assessed by univariate and multivariate analyses the risk factors for poor outcomes. Results Overall, we included 91 LTx who contracted COVID-19. The COVID-19 in-hospital mortality rate reached 4.4%. By hierarchical clustering, we found a strong and independent association between the composite poor outcome and the discontinuation of at least one immunosuppressive molecule among tacrolimus, cyclosporine, mycophenolate mofetil, and everolimus. Obesity (OR = 16, 95%CI (1.96; 167), p = 0.01) and chronic renal failure (OR = 4.6, 95%CI (1.4; 18), p = 0.01) were also independently associated with the composite poor outcome. Conversely, full vaccination was protective (OR = 0.23, 95%CI (0.046; 0.89), p = 0.047). Conclusion The administration of immunosuppressive drugs such as tacrolimus, cyclocporine or everolimus can have a protective effect in LTx with COVID-19, probably related to their intrinsic antiviral capacity.
Supplementary Information The online version contains supplementary material available at https://doi. org/10.1186/s12879-024-09269-1. Supplementary Material 1 Author contributions Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Due to the retrospective nature of the study, the need for informed consent was waived by the Ethics Committee of the Société de Pneumologie de Langue Française (CEPRO) (number CEPRO2023-036) Competing interests The authors declare no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Aversa, Benvenuto, Anderson, COVID-19 in lung transplant recipients: a single center case series from New York City, Am J Transpl
Avery, Chiang, Marr, Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: a retrospective cohort, Am J Transpl
Belli, Fondevila, Cortesi, Protective role of Tacrolimus, Deleterious Role of Age and comorbidities in Liver Transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study, Gastroenterology
Bösch, Börner, Kemmner, Attenuated early inflammatory response in solid organ recipients with COVID-19, Clin Transpl
Carbajo-Lozoya, Ma-Lauer, Malešević, Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir, Virus Res
Choi, Li, Hao, Yao, Guan, Immunosuppressive therapy and COVID-19 infection in patients with NMOSD, Immun Inflamm Dis
Coiffard, Lepper, Prud'homme, Management of lung transplantation in the COVID-19 era-An international survey, Am J Transpl
Colson, Fournier, Chaudet, Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the role of globalization and zoonosis in Pandemics, Front Microbiol
De Andrade, De Sandes-Freitas, Requião-Moura, Development and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients, Am J Transpl
Desmazes-Dufeu, Coltey, Amari, Discordant courses of COVID-19 in a cohabiting couple of lung transplant recipients, Transpl Infect Dis
Forchette, Sebastian, Liu, A Comprehensive Review of COVID-19 Virology, vaccines, variants, and therapeutics, Curr Med Sci
Garcia, Sharma, Ramaiah, Antiviral drug screen identifies DNAdamage response inhibitor as potent blocker of SARS-CoV-2 replication, Cell Rep
Gatti, Rinaldi, Bussini, Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis, Clin Microbiol Infect
Ge, Li, Wu, Candido, Wei, Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study, PLoS ONE
Heldman, Kates, Safa, COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: a comparative analysis from a multicenter study, Am J Transpl
Husson, Josse, Lê, FactoMineR: an R Package for Multivariate Analysis, J Stat Softw
Kamp, Hinrichs, Fuge, Ewen, Gottlieb, COVID-19 in lung transplant recipients-risk prediction and outcomes, PLoS ONE
Karruli, Spiezia, Boccia, Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: systematic review and meta-analysis, Transpl Infect Dis
Liddicoat, Lavelle, Modulation of innate immunity by cyclosporine A, Biochem Pharmacol
Manuel, Estabrook, American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, Clin Transpl
Merli, Pasulo, Perricone, Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients, J Infect
Messika, Eloy, Roux, COVID-19 in lung transplant recipients, Transplantation
Nguyen, Houhamdi, Meddeb, Colson, Gautret, Reinfection with SARS-CoV-2 Omicron BA.4 and BA.5 variants, J Med Virol
Ogando, Metscher, Moes, The cyclophilin-dependent calcineurin inhibitor voclosporin inhibits SARS-CoV-2 replication in Cell Culture, Transpl Int
Pinchera, Spirito, Buonomo, mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study, Frontiers in Medicine, doi:10.3389/fmed.2022.852973
Pizzorno, Padey, Dubois, In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2, Antiviral Res
Polack, Thomas, Kitchin, Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med
Ringer, Azmy, Kaman, A retrospective matched cohort singlecenter study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients, Transpl Infect Dis
Roosma, Van Gemert, De Zwart, The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: a multicenter experience, J Heart Lung Transpl
Sabbatini, Ruggiero, Palatucci, Oscillatory mTOR inhibition and Treg increase in kidney transplantation, Clin Exp Immunol
Terrazzano, Rubino, Palatucci, Giovazzino, Carriero et al., An Open question: is it rational to inhibit the mtor-dependent pathway as COVID-19 therapy?, Front Pharmacol
Thakur, Bhola, Thakur, Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe, Infection
Trapani, Masiero, Puoti, Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: a nationwide populationbased study, Am J Transpl
Trindade, Chapin, Gannon, Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients, Transpl Infect Dis
Verleden, Glanville, Lease, Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT, J Heart Lung Transpl
Weder, Kadl, Longitudinal impact of COVID-19 on lung function in lung transplant recipients: time to stop worrying?, Transpl Infect Dis
Willicombe, Thomas, Mcadoo, COVID-19 and calcineurin inhibitors: should they get left out in the storm?, J Am Soc Nephrol
Zimmermann, Glueck, Fertmann, COVID-19 in recent lung transplant recipients: clinical outcomes and management strategies, Transpl Proc
{ 'indexed': {'date-parts': [[2024, 5, 28]], 'date-time': '2024-05-28T17:40:18Z', 'timestamp': 1716918018350}, 'reference-count': 41, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 5, 28]], 'date-time': '2024-05-28T00:00:00Z', 'timestamp': 1716854400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2024, 5, 28]], 'date-time': '2024-05-28T00:00:00Z', 'timestamp': 1716854400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>The aim of this study was to assess the impact of immunosuppression ' 'management on coronavirus disease 2019 (COVID-19) outcomes.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>We performed a single-center retrospective study in a cohort of 358 ' 'lung transplant recipients (LTx) over the period from March 2020 to April 2022. All included ' 'symptomatic patients had at least one positive SARS-CoV-2 rt-PCR. We used a composite primary ' 'outcome for COVID-19 including increased need for oxygen since the hospital admission, ICU ' 'transfer, and in-hospital mortality. We assessed by univariate and multivariate analyses the ' 'risk factors for poor outcomes.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Overall, we included 91 LTx who contracted COVID-19. The COVID-19 ' 'in-hospital mortality rate reached 4.4%. By hierarchical clustering, we found a strong and ' 'independent association between the composite poor outcome and the discontinuation of at ' 'least one immunosuppressive molecule among tacrolimus, cyclosporine, mycophenolate mofetil, ' 'and everolimus. Obesity (OR\u2009=\u200916, 95%CI (1.96; 167), ' '<jats:italic>p</jats:italic>\u2009=\u20090.01) and chronic renal failure (OR\u2009=\u20094.6, ' '95%CI (1.4; 18), <jats:italic>p</jats:italic>\u2009=\u20090.01) were also independently ' 'associated with the composite poor outcome. Conversely, full vaccination was protective ' '(OR\u2009=\u20090.23, 95%CI (0.046; 0.89), <jats:italic>p</jats:italic>\u2009=\u2009' '0.047).</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>The administration of immunosuppressive drugs such as tacrolimus, ' 'cyclocporine or everolimus can have a protective effect in LTx with COVID-19, probably ' 'related to their intrinsic antiviral capacity.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s12879-024-09269-1', 'type': 'journal-article', 'created': {'date-parts': [[2024, 5, 28]], 'date-time': '2024-05-28T15:08:55Z', 'timestamp': 1716908935000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Management of immunosuppression in lung transplant recipients and COVID-19 outcomes: an ' 'observational retrospective cohort-study', 'prefix': '10.1186', 'volume': '24', 'author': [ {'given': 'Hugo', 'family': 'Bes-Berlandier', 'sequence': 'first', 'affiliation': []}, {'given': 'Benjamin', 'family': 'Coiffard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Julien', 'family': 'Bermudez', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nadine', 'family': 'Demazes-dufeu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bérengère', 'family': 'Coltey', 'sequence': 'additional', 'affiliation': []}, {'given': 'Céline', 'family': 'Boschi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Philippe', 'family': 'Colson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sami', 'family': 'Hraiech', 'sequence': 'additional', 'affiliation': []}, {'given': 'Martine', 'family': 'Reynaud-Gaubert', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nadim', 'family': 'Cassir', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 5, 28]]}, 'reference': [ { 'key': '9269_CR1', 'doi-asserted-by': 'publisher', 'first-page': 'e0258154', 'DOI': '10.1371/journal.pone.0258154', 'volume': '16', 'author': 'E Ge', 'year': '2021', 'unstructured': 'Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing ' 'comorbidities with mortality and disease severity among 167,500 ' 'individuals with COVID-19 in Canada: a population-based cohort study. ' 'PLoS ONE. 2021;16:e0258154.', 'journal-title': 'PLoS ONE'}, { 'key': '9269_CR2', 'doi-asserted-by': 'publisher', 'first-page': '2509', 'DOI': '10.1111/ajt.16428', 'volume': '21', 'author': 'S Trapani', 'year': '2021', 'unstructured': 'Trapani S, Masiero L, Puoti F, et al. Incidence and outcome of ' 'SARS-CoV-2 infection on solid organ transplantation recipients: a ' 'nationwide population-based study. Am J Transpl. 2021;21:2509–21.', 'journal-title': 'Am J Transpl'}, { 'key': '9269_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1057', 'DOI': '10.1016/j.cmi.2022.02.039', 'volume': '28', 'author': 'M Gatti', 'year': '2022', 'unstructured': 'Gatti M, Rinaldi M, Bussini L, et al. Clinical outcome in solid organ ' 'transplant recipients affected by COVID-19 compared to general ' 'population: a systematic review and meta-analysis. Clin Microbiol ' 'Infect. 2022;28:1057–65.', 'journal-title': 'Clin Microbiol Infect'}, { 'key': '9269_CR4', 'doi-asserted-by': 'publisher', 'first-page': 'e13967', 'DOI': '10.1111/tid.13967', 'volume': '24', 'author': 'AJ Trindade', 'year': '2022', 'unstructured': 'Trindade AJ, Chapin KC, Gannon WD, et al. Clinical course of SARS-CoV-2 ' 'infection and recovery in lung transplant recipients. Transpl Infect ' 'Dis. 2022;24:e13967.', 'journal-title': 'Transpl Infect Dis'}, { 'key': '9269_CR5', 'doi-asserted-by': 'publisher', 'first-page': '3072', 'DOI': '10.1111/ajt.16241', 'volume': '20', 'author': 'M Aversa', 'year': '2020', 'unstructured': 'Aversa M, Benvenuto L, Anderson M, et al. COVID-19 in lung transplant ' 'recipients: a single center case series from New York City. Am J ' 'Transpl. 2020;20:3072–80.', 'journal-title': 'Am J Transpl'}, { 'key': '9269_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1237', 'DOI': '10.1016/j.healun.2022.06.011', 'volume': '41', 'author': 'E Roosma', 'year': '2022', 'unstructured': 'Roosma E, van Gemert JP, de Zwart AES, et al. The effect of COVID-19 on ' 'transplant function and development of CLAD in lung transplant patients: ' 'a multicenter experience. J Heart Lung Transpl. 2022;41:1237–47.', 'journal-title': 'J Heart Lung Transpl'}, { 'key': '9269_CR7', 'doi-asserted-by': 'publisher', 'first-page': 'e13511', 'DOI': '10.1111/ctr.13511', 'volume': '33', 'author': 'O Manuel', 'year': '2019', 'unstructured': 'Manuel O, Estabrook M, American Society of Transplantation Infectious ' 'Diseases Community of Practice. RNA respiratory viral infections in ' 'solid organ transplant recipients: guidelines from the American Society ' 'of Transplantation Infectious Diseases Community of Practice. Clin ' 'Transpl. 2019;33:e13511.', 'journal-title': 'Clin Transpl'}, { 'key': '9269_CR8', 'doi-asserted-by': 'publisher', 'first-page': 'e13556', 'DOI': '10.1111/tid.13556', 'volume': '23', 'author': 'M Ringer', 'year': '2021', 'unstructured': 'Ringer M, Azmy V, Kaman K, et al. A retrospective matched cohort ' 'single-center study evaluating outcomes of COVID-19 and the impact of ' 'immunomodulation on COVID-19-related cytokine release syndrome in solid ' 'organ transplant recipients. Transpl Infect Dis. 2021;23:e13556.', 'journal-title': 'Transpl Infect Dis'}, { 'key': '9269_CR9', 'doi-asserted-by': 'publisher', 'first-page': '2498', 'DOI': '10.1111/ajt.16431', 'volume': '21', 'author': 'RK Avery', 'year': '2021', 'unstructured': 'Avery RK, Chiang TP-Y, Marr KA, et al. Inpatient COVID-19 outcomes in ' 'solid organ transplant recipients compared to non-solid organ transplant ' 'patients: a retrospective cohort. Am J Transpl. 2021;21:2498–508.', 'journal-title': 'Am J Transpl'}, { 'key': '9269_CR10', 'doi-asserted-by': 'publisher', 'first-page': '856', 'DOI': '10.3389/fphar.2020.00856', 'volume': '11', 'author': 'G Terrazzano', 'year': '2020', 'unstructured': 'Terrazzano G, Rubino V, Palatucci AT, Giovazzino A, Carriero F, Ruggiero ' 'G. An Open question: is it rational to inhibit the mtor-dependent ' 'pathway as COVID-19 therapy? Front Pharmacol. 2020;11:856.', 'journal-title': 'Front Pharmacol'}, { 'key': '9269_CR11', 'doi-asserted-by': 'publisher', 'first-page': '104878', 'DOI': '10.1016/j.antiviral.2020.104878', 'volume': '181', 'author': 'A Pizzorno', 'year': '2020', 'unstructured': 'Pizzorno A, Padey B, Dubois J, et al. In vitro evaluation of antiviral ' 'activity of single and combined repurposable drugs against SARS-CoV-2. ' 'Antiviral Res. 2020;181:104878.', 'journal-title': 'Antiviral Res'}, { 'key': '9269_CR12', 'doi-asserted-by': 'publisher', 'first-page': 'e14027', 'DOI': '10.1111/ctr.14027', 'volume': '34', 'author': 'F Bösch', 'year': '2020', 'unstructured': 'Bösch F, Börner N, Kemmner S, et al. Attenuated early inflammatory ' 'response in solid organ recipients with COVID-19. Clin Transpl. ' '2020;34:e14027.', 'journal-title': 'Clin Transpl'}, { 'key': '9269_CR13', 'unstructured': 'Clinical Spectrum. ' 'https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. ' 'Accessed 18 August 2023.'}, { 'key': '9269_CR14', 'doi-asserted-by': 'publisher', 'first-page': '493', 'DOI': '10.1016/j.healun.2019.03.009', 'volume': '38', 'author': 'GM Verleden', 'year': '2019', 'unstructured': 'Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft ' 'dysfunction: definition, diagnostic criteria, and approaches to ' 'treatment-A consensus report from the Pulmonary Council of the ISHLT. J ' 'Heart Lung Transpl. 2019;38:493–503.', 'journal-title': 'J Heart Lung Transpl'}, { 'key': '9269_CR15', 'doi-asserted-by': 'publisher', 'first-page': '786233', 'DOI': '10.3389/fmicb.2021.786233', 'volume': '12', 'author': 'P Colson', 'year': '2021', 'unstructured': 'Colson P, Fournier P-E, Chaudet H, et al. Analysis of SARS-CoV-2 ' 'variants from 24,181 patients exemplifies the role of globalization and ' 'zoonosis in Pandemics. Front Microbiol. 2021;12:786233.', 'journal-title': 'Front Microbiol'}, { 'key': '9269_CR16', 'doi-asserted-by': 'publisher', 'first-page': 'e29033', 'DOI': '10.1002/jmv.29033', 'volume': '95', 'author': 'NN Nguyen', 'year': '2023', 'unstructured': 'Nguyen NN, Houhamdi L, Meddeb L, Colson P, Gautret P. Reinfection with ' 'SARS-CoV-2 Omicron BA.4 and BA.5 variants. J Med Virol. 2023;95:e29033.', 'journal-title': 'J Med Virol'}, { 'key': '9269_CR17', 'unstructured': 'Polack FP, Thomas SJ, Kitchin N et al. Safety and Efficacy of the ' 'BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;:NEJMoa2034577.'}, { 'key': '9269_CR18', 'unstructured': 'Coronavirus Disease 2019 (COVID-19)| CDC. ' 'https://www.cdc.gov/coronavirus/2019-nCoV/index.html. Accessed 18 August ' '2023.'}, { 'key': '9269_CR19', 'unstructured': 'R: The R Project for Statistical Computing. https://www.r-project.org/. ' 'Accessed 23 September 2023.'}, { 'key': '9269_CR20', 'doi-asserted-by': 'crossref', 'unstructured': 'Husson F, Josse J, Lê S. FactoMineR: an R Package for Multivariate ' 'Analysis. J Stat Softw 2008; 25.', 'DOI': '10.18637/jss.v025.i01'}, { 'key': '9269_CR21', 'doi-asserted-by': 'publisher', 'first-page': '1586', 'DOI': '10.1111/ajt.16368', 'volume': '21', 'author': 'B Coiffard', 'year': '2021', 'unstructured': 'Coiffard B, Lepper PM, Prud’Homme E, et al. Management of lung ' 'transplantation in the COVID-19 era-An international survey. Am J ' 'Transpl. 2021;21:1586–96.', 'journal-title': 'Am J Transpl'}, { 'key': '9269_CR22', 'doi-asserted-by': 'publisher', 'first-page': '2774', 'DOI': '10.1111/ajt.16692', 'volume': '21', 'author': 'MR Heldman', 'year': '2021', 'unstructured': 'Heldman MR, Kates OS, Safa K, et al. COVID-19 in hospitalized lung and ' 'non-lung solid organ transplant recipients: a comparative analysis from ' 'a multicenter study. Am J Transpl. 2021;21:2774–84.', 'journal-title': 'Am J Transpl'}, { 'key': '9269_CR23', 'doi-asserted-by': 'publisher', 'unstructured': 'Pinchera B, Spirito L, Buonomo AR et al. mTOR Inhibitor Use Is ' 'Associated With a Favorable Outcome of COVID-19 in Patients of Kidney ' 'Transplant: Results of a Retrospective Study. Frontiers in Medicine. ' '2022; 9. ' 'https://www.frontiersin.org/articles/https://doi.org/10.3389/fmed.2022.852973. ' 'Accessed 14 July 2022.', 'DOI': '10.3389/fmed.2022.852973'}, { 'key': '9269_CR24', 'doi-asserted-by': 'publisher', 'first-page': '1151', 'DOI': '10.1053/j.gastro.2020.11.045', 'volume': '160', 'author': 'LS Belli', 'year': '2021', 'unstructured': 'Belli LS, Fondevila C, Cortesi PA, et al. Protective role of Tacrolimus, ' 'Deleterious Role of Age and comorbidities in Liver Transplant recipients ' 'with Covid-19: results from the ELITA/ELTR multi-center European study. ' 'Gastroenterology. 2021;160:1151–e11633.', 'journal-title': 'Gastroenterology'}, { 'key': '9269_CR25', 'doi-asserted-by': 'crossref', 'unstructured': 'Desmazes-Dufeu N, Coltey B, Amari L et al. Discordant courses of ' 'COVID-19 in a cohabiting couple of lung transplant recipients. Transpl ' 'Infect Dis 2020;:e13410.', 'DOI': '10.1111/tid.13410'}, { 'key': '9269_CR26', 'doi-asserted-by': 'publisher', 'first-page': '108940', 'DOI': '10.1016/j.celrep.2021.108940', 'volume': '35', 'author': 'G Garcia', 'year': '2021', 'unstructured': 'Garcia G, Sharma A, Ramaiah A, et al. Antiviral drug screen identifies ' 'DNA-damage response inhibitor as potent blocker of SARS-CoV-2 ' 'replication. Cell Rep. 2021;35:108940.', 'journal-title': 'Cell Rep'}, { 'key': '9269_CR27', 'doi-asserted-by': 'publisher', 'first-page': '230', 'DOI': '10.1111/cei.12669', 'volume': '182', 'author': 'M Sabbatini', 'year': '2015', 'unstructured': 'Sabbatini M, Ruggiero G, Palatucci AT, et al. Oscillatory mTOR ' 'inhibition and Treg increase in kidney transplantation. Clin Exp ' 'Immunol. 2015;182:230–40.', 'journal-title': 'Clin Exp Immunol'}, { 'key': '9269_CR28', 'doi-asserted-by': 'publisher', 'first-page': '1145', 'DOI': '10.1681/ASN.2020030348', 'volume': '31', 'author': 'M Willicombe', 'year': '2020', 'unstructured': 'Willicombe M, Thomas D, McAdoo S. COVID-19 and calcineurin inhibitors: ' 'should they get left out in the storm? J Am Soc Nephrol. 2020;31:1145–6.', 'journal-title': 'J Am Soc Nephrol'}, { 'key': '9269_CR29', 'doi-asserted-by': 'publisher', 'first-page': '44', 'DOI': '10.1016/j.virusres.2014.02.010', 'volume': '184', 'author': 'J Carbajo-Lozoya', 'year': '2014', 'unstructured': 'Carbajo-Lozoya J, Ma-Lauer Y, Malešević M, et al. Human coronavirus NL63 ' 'replication is cyclophilin A-dependent and inhibited by ' 'non-immunosuppressive cyclosporine A-derivatives including Alisporivir. ' 'Virus Res. 2014;184:44–53.', 'journal-title': 'Virus Res'}, { 'key': '9269_CR30', 'doi-asserted-by': 'publisher', 'first-page': '10369', 'DOI': '10.3389/ti.2022.10369', 'volume': '35', 'author': 'NS Ogando', 'year': '2022', 'unstructured': 'Ogando NS, Metscher E, Moes DJAR, et al. The cyclophilin-dependent ' 'calcineurin inhibitor voclosporin inhibits SARS-CoV-2 replication in ' 'Cell Culture. Transpl Int. 2022;35:10369.', 'journal-title': 'Transpl Int'}, { 'key': '9269_CR31', 'doi-asserted-by': 'publisher', 'first-page': '472', 'DOI': '10.1016/j.bcp.2019.03.022', 'volume': '163', 'author': 'AM Liddicoat', 'year': '2019', 'unstructured': 'Liddicoat AM, Lavelle EC. Modulation of innate immunity by cyclosporine ' 'A. Biochem Pharmacol. 2019;163:472–80.', 'journal-title': 'Biochem Pharmacol'}, { 'key': '9269_CR32', 'doi-asserted-by': 'publisher', 'first-page': 'e13595', 'DOI': '10.1111/tid.13595', 'volume': '23', 'author': 'A Karruli', 'year': '2021', 'unstructured': 'Karruli A, Spiezia S, Boccia F, et al. Effect of immunosuppression ' 'maintenance in solid organ transplant recipients with COVID-19: ' 'systematic review and meta-analysis. Transpl Infect Dis. 2021;23:e13595.', 'journal-title': 'Transpl Infect Dis'}, { 'key': '9269_CR33', 'doi-asserted-by': 'publisher', 'first-page': '414', 'DOI': '10.1016/j.jinf.2020.10.024', 'volume': '82', 'author': 'M Merli', 'year': '2021', 'unstructured': 'Merli M, Pasulo L, Perricone G, et al. Impact of immunosuppressive ' 'therapy on the severity of COVID-19 in solid organ transplant ' 'recipients. J Infect. 2021;82:414–51.', 'journal-title': 'J Infect'}, { 'key': '9269_CR34', 'doi-asserted-by': 'publisher', 'first-page': '610', 'DOI': '10.1111/ajt.16807', 'volume': '22', 'author': 'LG Modelli de Andrade', 'year': '2022', 'unstructured': 'Modelli de Andrade LG, de Sandes-Freitas TV, Requião-Moura LR, et al. ' 'Development and validation of a simple web-based tool for early ' 'prediction of COVID-19-associated death in kidney transplant recipients. ' 'Am J Transpl. 2022;22:610–25.', 'journal-title': 'Am J Transpl'}, { 'key': '9269_CR35', 'doi-asserted-by': 'publisher', 'first-page': 'e1128', 'DOI': '10.1002/iid3.1128', 'volume': '12', 'author': 'UW Choi', 'year': '2024', 'unstructured': 'Choi UW, Ai X, Li H, Hao Y, Yao X, Guan Y. Immunosuppressive therapy and ' 'COVID-19 infection in patients with NMOSD. Immun Inflamm Dis. ' '2024;12:e1128.', 'journal-title': 'Immun Inflamm Dis'}, { 'key': '9269_CR36', 'doi-asserted-by': 'crossref', 'unstructured': 'Weder MM, Kadl A. Longitudinal impact of COVID-19 on lung function in ' 'lung transplant recipients: time to stop worrying? Transpl Infect Dis ' '2023;:e14131.', 'DOI': '10.1111/tid.14131'}, { 'key': '9269_CR37', 'doi-asserted-by': 'publisher', 'first-page': '309', 'DOI': '10.1007/s15010-021-01734-2', 'volume': '50', 'author': 'V Thakur', 'year': '2022', 'unstructured': 'Thakur V, Bhola S, Thakur P, et al. Waves and variants of SARS-CoV-2: ' 'understanding the causes and effect of the COVID-19 catastrophe. ' 'Infection. 2022;50:309–25.', 'journal-title': 'Infection'}, { 'key': '9269_CR38', 'doi-asserted-by': 'publisher', 'first-page': '1037', 'DOI': '10.1007/s11596-021-2395-1', 'volume': '41', 'author': 'L Forchette', 'year': '2021', 'unstructured': 'Forchette L, Sebastian W, Liu T. A Comprehensive Review of COVID-19 ' 'Virology, vaccines, variants, and therapeutics. Curr Med Sci. ' '2021;41:1037–51.', 'journal-title': 'Curr Med Sci'}, { 'key': '9269_CR39', 'doi-asserted-by': 'publisher', 'first-page': '1504', 'DOI': '10.1016/j.transproceed.2021.12.014', 'volume': '54', 'author': 'J Zimmermann', 'year': '2022', 'unstructured': 'Zimmermann J, Glueck OM, Fertmann JM, et al. COVID-19 in recent lung ' 'transplant recipients: clinical outcomes and management strategies. ' 'Transpl Proc. 2022;54:1504–16.', 'journal-title': 'Transpl Proc'}, { 'key': '9269_CR40', 'doi-asserted-by': 'publisher', 'first-page': '177', 'DOI': '10.1097/TP.0000000000003508', 'volume': '105', 'author': 'J Messika', 'year': '2021', 'unstructured': 'Messika J, Eloy P, Roux A, et al. COVID-19 in lung transplant ' 'recipients. Transplantation. 2021;105:177–86.', 'journal-title': 'Transplantation'}, { 'key': '9269_CR41', 'doi-asserted-by': 'publisher', 'first-page': 'e0257807', 'DOI': '10.1371/journal.pone.0257807', 'volume': '16', 'author': 'JC Kamp', 'year': '2021', 'unstructured': 'Kamp JC, Hinrichs JB, Fuge J, Ewen R, Gottlieb J. COVID-19 in lung ' 'transplant recipients-risk prediction and outcomes. PLoS ONE. ' '2021;16:e0257807.', 'journal-title': 'PLoS ONE'}], 'container-title': 'BMC Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-024-09269-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s12879-024-09269-1/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-024-09269-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 5, 28]], 'date-time': '2024-05-28T15:09:06Z', 'timestamp': 1716908946000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09269-1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 5, 28]]}, 'references-count': 41, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}}, 'alternative-id': ['9269'], 'URL': 'http://dx.doi.org/10.1186/s12879-024-09269-1', 'relation': {}, 'ISSN': ['1471-2334'], 'subject': [], 'container-title-short': 'BMC Infect Dis', 'published': {'date-parts': [[2024, 5, 28]]}, 'assertion': [ { 'value': '28 January 2024', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '28 March 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '28 May 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'Due to the retrospective nature of the study, the need for informed consent was ' 'waived by the Ethics Committee of the Société de Pneumologie de Langue ' 'Française (CEPRO) (number CEPRO2023-036)', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'The authors declare no competing interests.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '536'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit